A wide range of stem cell research towards regenerative medicine has been conducted in a large number of domains in the world over the years. However, those produced data and information are not fully utilized and sometimes causes failure to be reproduced among laboratories or cell banks due to a lack of standardization of cellular assay reporting formats. To maximize a value placed on the information in stem cell and derivative cell research, we have proposed reporting guidelines for describing cellular assay data to pursue the facilitation of practical regenerative medicine named Minimum Information About a Cellular Assay for Regenerative Medicine (MIACARM). MIACARM has been developed based on the existing Minimum Information About a Cellular Assay (MIACA) with defined taxonomy of human cell types, which allows for the description of advanced cellular experiments. MIACARM is applicable for exchanging data not only for basic cellular assay, but also for stem cell assay data that are produced and provided by cell banks, registries, or other academic institutions all over the world. Here, we introduce our recent progress on developing stem cell data retrieval system based on MIACARM.
INTRODUCTION
After decades of the invention of the first human embryonic stem (hES) cells in 1998 [1] and human induces pluripotent stem (hiPS) cells in 2007 [2] , there have been enormous amount of studies performed to investigate cellular properties of the human body. Especially, there are vast amounts of assay data that have been produced to elucidate the mechanisms for generation of diverse cell types from a single zygote or pathogenic mechanism based on various cellular properties in research field of regenerative medicine. For the use of stem cells in clinical application, rigorous quality checks of engineered cells are essential for judging their safety and effectiveness for therapeutic application.
To regulate the quality and safety of engineered cells for regenerative medicine, assay data and information must be compared to those of naturally existing cells as reference.
The number of hiPS and hES cells established by large-scale international initiatives is increasing dramatically [3] , and at the same time, cellular data and information have been accumulated in stem cell banks around the world.
Cellular information has been stored in cell banks and is available to the general public. At the same time, there are information repositories which collect cellular information from such cell banks or academic laboratories and provide information according to their own formats.
Although the number of produced cellular data has been multiplied dramatically, it is still hard to fully utilize them due to a lack of standardization of cellular assay reporting formats. It consequently causes difficulties in experimental reproducibility and data exchange among cell banks and laboratories. To enhance the information flow, it is essential to create a list of items which is clarified as minimum, yet indispensable, for any cellular assay data including the field of regenerative medicine, to describe the data and information in a standardized way which can be efficiently stored and shared.
To address this challenge, we developed Minimum Information About a Cellular Assay for Regenerative Medicine (MIACARM) [4] , which would allow for the report of advanced cellular experiments with defined taxonomy of human cell types by international collaboration.
Using MIACARM, we are currently working on developing an information retrieval system by efforts made through cooperation of several stem cell banks and registries around the world.
RESULTS

MIACARM consists of two levels of guidelines
MIACARM consists of two levels of guidelines, MIACARM-I and -II (Figure 1) .
MIACARM-I has items to describe omics assays in basic research using human cells, and MIACARM-II has items for practical regenerative medicine which include items for quality and safety of cells. Both MIACARM-I and -II are combined to serve as a reporting guideline for exchanging, maintenance, and reproducibility of cellular assay data.
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Development of MIACARM Based on MIACA
Basic structure of MIACARM was created by reorganizing the existing Minimum Information About a Cellular Assay (MIACA) [5] into five-top modules composed of Project, Source Cell, Assay, Experimental Technology, and Data (Figure 1 ), based on the structure design of the Gene Expression Omnibus (GEO) [6] for enabling a description of experimental procedure and cellular information items. MIACARM consists of 257 items that are required to report cellular assays in terms of reproducibility, quality, safety, and efficacy of product cells, which are simply summarized in Table 1 . We newly added 144 items and divided into two new sections which are named Stem Cell Production and Stem Cell Quality Control, in the Source Cell module of MIACARM-II, based on two publications on stem cell banking [7, 8] and four regulations for products from (stem) cells or tissues in Japan, the U.S., and Europe [9] [10] [11] [12] .
Validating Items in MIACARM-II As Minimum Information
When we validated 144 items in MIACARM-II by scoring the numbers of source references (out of 6) and stem cell banks (out of 11) that adopted it, there were distinctive patterns observed on item distribution [4] . 50 items that received high scores from both source references and stem cell banks are considered as important information for stem cell research and application, and those are items related to culture conditions of stem cells, some stem cell characteristics items such as karyotyping and in vitro differentiation ability, and source cell identifications. The group of 18 items which received high scores from stem cell banks includes attributes associated with stem cell materials and biological information of source cell donor. 75 items with high scores from source references are mainly about experimental materials used in the stem and source cell culture and establishment such as basal medium and feeder cell names.
Among 144 items, there are 10 items which are possibly considered as linkers to the private information of donors such as gender, health/disease history, human leukocyte antigen (HLA) types, single nucleotide polymorphisms (SNPs), and copy number variation (CNV). Among those, we summarised gene expression profiling data found in MIACARM in Table 2 . For genome profiling data, each of them contains different amount of genome information as shown in Table 2 . Although these types of information and data cannot be provided due to privacy issues, they are recognised as critical characterizations for determining safety of established stem cells used as clinical products. For example, SNPs are used as an index of cancer risk [13, 14] .
Developing global cellular information retrieval system based on MIACARM
Using MIACARM, we are currently working on developing an information retrieval system by efforts made through cooperation with RUCDR Infinite Biologics (http://www.rucdr.org), UK Stem Cell Bank (http://www.nibsc.org), Stemcell Knowledge and Information Portal (https://www.skip.med.keio.ac.jp/en/) and European human Pluripotent Stem Cell Registry (http://hpscreg.eu). To develop the cellular information retrieval system, we have proposed to use application programming interface (API) to access and cross-search the information in stem cell banks, and search results are shown in standardized format which is created based on MIACARM items (Figure 2) . We further plan to create a global data exchange network to enhance information flow among various cell banks or registries that have been established at more than 20 sites in the world. Once this system is developed, it will allow researchers to omnibus-search for the query across multiple stem cell banks/registries.
DISCUSSION
We have proposed for the first time a minimum information reporting guideline to describe cellular assay data efficiently and sufficiently for the
MIACARM items
No. of source reference adopted
No. of stem cell banks adopted facilitation of practical regenerative medicine [4] . By using MIACARM-I and -II, it is expected to enable standardization of experimental items to be reported with defined taxonomy of human cell types and controlled terms, description of production procedures, and quality checks of stem cells. We also anticipate that MIACARM will provide a framework of platform for exchanging cellular assay data among cell banks and registries around the world. Furthermore, by creating a global data exchange network among various cell banks or registries with MIACARM, it will greatly reduce time and costs caused by unintended experimental duplications that often happen in distinct organizations.
Recently, there has been an effort made for sharing genomic and clinical data by the Global Alliance for Genomics and Health [21] . In this effort, there are some tools developed to share or exchange genotypic and phenotypic information by using API. We also plan to use web API for stem cell information retrieval system. However, issues which are associated with privacy protection of shared information still remain to be carefully considered. Especially for each type of gene analysis data which contain different rate of genome information, as it was briefly summarized in Table 2 . Setting different levels of protection may be relevant for such data. Genome and epigenome profiling data should be rigorously protected as they have high content rate of genomic information. In addition to those data, SNP profiling data is also considered as a possible identifier of individuals by combining with other metadata of donors since it is deeply correlated to phenotypic variation [22, 23] , even though content rate of genomic information of SNP data is low. There is one recent report that describes a framework to produce privacy-preserving genome-wide association study results [24] . Since stem cell data also include donor and genome or gene expression profiling data of cells, privacy protection technologies or policies would require to be incorporated also in MIACARM based stem cell information retrieval system as a next step. 
